An aptamer‐based magnetic resonance imaging contrast agent for detecting oligomeric amyloid‐β in the brain of an Alzheimer's disease mouse model. (20th November 2022) - Kim, Sang‐Tae
Abstract: The oligomeric amyloid‐β (oAβ) is a reliable feature for an early diagnosis of Alzheimer's disease (AD). Therefore, the objective of this study was to demonstrate imaging of oAβ deposits using our developed DNA aptamer called ob5 conjugated with gadolinium (Gd)‐dodecane tetraacetic acid (DOTA) as a contrast agent for early diagnosis of AD using MRI. An oAβ‐specific aptamer was developed by amide bond formation and conjugated to Gd‐DOTA MRI contrast agent and/or cyanine5 (cy5). We verified the performance of our new contrast agent with an AD mouse model using in vivo and ex vivo fluorescent imaging and animal MRI experiments. The presence of soluble Aβ in 3xTg AD mice was detected using GdDOTA‐ob5‐cy5 probe ex vivo. Fluorescence intensities of the GdDOTA‐ob5‐cy5 contrast agent were high in the brains of 3xTg‐AD mice, but relatively low in the brains of control mice. The GdDOTA‐ob5 contrast agent had higher relaxivity than a clinically available contrast agent. T1‐weighted MRI signals in 5‐month‐old 3xTg AD mice increased at 5 min, were prolonged until 10 min, then decreased 15 min after injecting the GdDOTA‐ob5 contrast agent. Our targeted DNA aptamer GdDOTA‐ob5 contrast agent could be potentially useful for validating the efficacy of a novel diagnostic contrast agent for selectively targeting neurotoxic oAβ. It could ultimately be used for early diagnosis of AD. Abstract : We developed a DNA aptamer called ob5 conjugated with Gd‐DOTA as a contrast agent for early diagnosis of Alzheimer's disease (AD) using MRI and/or cyanine5 (cy5). Our developed contrast agent could be potentially useful for validating the efficacy of a novel diagnostic contrast agent for selectively targeting neurotoxic oligomeric amyloid‐β (oAβ).